<!DOCTYPE HTML>
<html lang="en">
<head>
	<meta charset="UTF-8">
	<title>VIKHI</title>
	<link rel="stylesheet" href="css/font-awesome/css/font-awesome.min.css" />

	<link rel="stylesheet" href="css/fonts/stylesheet.css" />
	<link rel="stylesheet" href="css/fonts/fonts.css" />
	<link rel="stylesheet" href="css/bootstrap/bootstrap.min.css" />
	<link rel="stylesheet" href="css/animat/animate.min.css" />
	<link rel="stylesheet" href="css/fancybox/jquery.fancybox.css" />
	<link rel="stylesheet" href="css/nivo-lightbox/nivo-lightbox.css" />
	<link rel="stylesheet" href="css/themes/default/default.css" />
	<link rel="stylesheet" href="css/owl-carousel/owl.carousel.css" />
	<link rel="stylesheet" href="css/owl-carousel/owl.theme.css" />
	<link rel="stylesheet" href="css/owl-carousel/owl.transitions.css">
	<link rel="stylesheet" href="css/style.css" />
	<link rel="stylesheet" href="css/responsive.css" />
	<link href="https://fonts.googleapis.com/css?family=Montserrat|Source+Sans+Pro" rel="stylesheet">



</head>
<body>

	<div class='preloader'><div class='loaded'>&nbsp;</div></div>

	<header id="home" class="header">
		<div class="main_menu_bg navbar-fixed-top">
			<div class="container">
				<div class="row">
					<div class="nave_menu">
					<nav class="navbar navbar-default">
					  <div class="container-fluid">
						<!-- Brand and toggle get grouped for better mobile display -->
						<div class="navbar-header">
						  <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#bs-example-navbar-collapse-1" aria-expanded="false">
						  </button>
						  <a class="navbar-brand" href="index.html">
							<div class="logo">
								<img src="images/vikhiLOGOsm.png" alt="" height="30"/>
							</div>
						  </a>
						</div>

						<!-- Collect the nav links, forms, and other content for toggling -->
						<div class="collapse navbar-collapse" id="bs-example-navbar-collapse-1">

						  <ul class="nav navbar-nav navbar-right">
							<li><a href="aspectos.html">1. General Aspects</a></li>
							<li><a href="recomendaciones.html">2. Recommendations</a></li>
							<li class="active"><a href="toxicidad00.html">3. Toxicities</a></li>
						  </ul>
						</div><!-- /.navbar-collapse -->
					  </div><!-- /.container-fluid -->
					</nav>
					</div>
				</div><!--Fin de row -->

			</div><!--Fin de container -->

		</div>
	</header> <!--Fin de header -->



	<section class="banner">
		<div class="container">
			<div class="row">
				<div class="main_banner_area text-center">
					<div class="col-md-12 col-sm-12">
						<div class="single_banner_text wow zoomIn" data-wow-duration="1s">
							<h2>Toxicities</h2>
							<br/>
							<div class="separator"></div>
							<h5>BASIC COURSE IN IMMUNOTHERAPY</h5>


						</div>
					</div>
				</div>
			</div>
		</div>
	</section><!-- Fin de Banner Section -->




	<section class="franja">
	 <div class="overlay_franja">
		 <div class="container">
			 <div class="row">
				 <div class="col-md-12 col-sm-12 col-xs-12">
					 <div class="main_franja_content text-center wow fadeIn" data-wow-duration="2s">
						 <h2>3<span class="negrita">.2</span> PULMONARY TOXICITY</h2>
						 <br/> <img src="images/ORGANOlungsSM.png" alt="" height="50px"/>
					 </div>
				 </div>
			 </div>
		 </div>
	 </div>
 </section>
 <section class="texto">
	 <div class="container">
		 <div class="row">
			 <div class="parrafo wow zoomIn" data-wow-duration="0.5s">
				 <p></p>
			 </div>
		 </div>
	 </div>
 </section>

	<section class="counterUp">
		<div class="counter_overlay">
			<div class="container">
				<div class="row">
					<div class="main_counter_content text-center">
						<div class="col-md-12 col-sm-12 col-xs-12">


							<h2>CLINICAL CASE</h2>
							<br/> <img src="images/pacienteICON.png" alt="" height="40px"/> <br/> <br/> <br/>
							<p>A 67-year-old patient, smoker and severe active alcoholic, with a history of severe chronic obstructive pulmonary disease, hypertension in medical treatment, intermittent claudication, transient ischaemic attack, hyperuricemia.</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Non-resectable cT4N0M0 p16-negative squamous cell carcinoma at the base of the tongue, treated with chemo-radiotherapy with poor tolerance and partial response</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Local progression 4 months after completion of treatment</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Nivolumab (compassionate use) 3 mg/kg every 2 weeks</p>
							<br/><br/> <img src="images/medicinas.png" alt="" height="40px"/> <br/><br/>
							<p>After the 4th administration of the treatment, the patient attended a consultation for reassessment with computed tomography (CT). The patient reported dry and mild cough, worsening of normal dyspnoea.</p>

						</div>
					</div>
				</div>
			</div>
		</div>
	</section>

	<section class="texto">
		<div class="container">
			<div class="row">
				<div class="parrafo wow zoomIn" data-wow-duration="0.5s">

									<img src="images/pulmon.png" alt="" height="300px"/>

									<div class="col-md-6 col-sm-6 col-xs-12">
											<p><span class="negrita">•</span> Appearance of bilateral lung infiltrates, predominantly at the right base.</p>
											<br/>
											<p><span class="negrita">•</span> Neck MRI: partial response</p>

									</div>

					</div>
				</div>
			</div>
		</section>




	<section class="counterUp">
		<div class="counter_overlay">
			<div class="container">
				<div class="row">
					<div class="main_counter_content text-center">
						<div class="col-md-12 col-sm-12 col-xs-12">


							<h2>Is it pulmonary toxicity to immunotherapy? </h2>
							<br/> <br/>
							<p>The incidence of pneumonitis varies in different clinical trials depending on the drug used and the type of cancer treated, but it is accepted that it is a rare event that occurs in less than 10% of patients (Chen, Ann Oncol 2015). However, it should be noted that it represents one of the most serious complications and may result in the death of the patient.</p>
							<br/>
							<p>There is a huge variability in frequency, time of appearance, characteristics, severity, management and prognosis, so a great effort is being made to study all these aspects.</p>
							<br/>
							<p>In the case of treatment with anti-CTLA4, and more specifically Ipilimumab, it is a very rare complication (&lt;1%), but with anti-PD1 and anti-PDL1 it is somewhat more frequent.</p>
							<br/>
							<p>This complication usually appears in the first 3 months in the case of anti-CTLA4 and in the first 6 in the case of anti-PD1. It tends to be resolved within around 3 <span class="cursiva">months (Weber, Cancer 2013)</span>. However, these data are highly variable and can be started even after the first dose (especially in the presence of pulmonary disease) or when immunotherapy has already stopped.</p>
							<br/> <br/> <br/> <br/> <img src="images/diagnostico.png" alt="" height="40px"/> <br/> <br/>
							<h2>Diagnosis</h2>
							<br/>
							<p><span class="decorado">&nbsp;Medical history&nbsp;</span></p>
							<br/>
							<p>The most common clinical symptoms are dyspnoea and non-productive cough. Other less common symptoms are fever and chest pain.</p>
							<br/>
							<p>One third of the patients are asymptomatic.</p>
							<br/>
							<p>It is often associated with other immunotherapy-related adverse events.</p>
							<br/>
							<p><span class="decorado">&nbsp;Risk factors (Possick J, Clin Chest Med 2017)&nbsp;</span></p>
							<br/>
							<p><span class="negrita">•</span> Type of cancer: Non-small cell lung carcinoma has a higher incidence of pneumonitis than melanoma. Patients with haematologic malignancies and head and neck squamous cell carcinomas also have high rates; however, the sample size we have is much lower, which does not allow us to draw conclusions.</p>
							<br/>
							<p><span class="negrita">•</span> Prior lung pathology including smoking (both smokers and ex-smokers).</p>
							<br/>
							<p><span class="negrita">•</span> Concurrent or sequential use of anti-PD1 and anti-CTLA4, being able to reach an incidence of 10% in these cases. Prior chemotherapy or radiation therapy are not clearly associated.</p>
							<br/>
							<p><span class="negrita">•</span> The expression of PDL1 has not been associated with an increased risk.</p>
							<br/>
							<p><span class="negrita">•</span> It has not been associated with the treatment line.</p>
							<br/>
							<p><span class="negrita">•</span> Response to treatment: in general, the response to treatment has not been associated with a higher rate of pneumonitis. In large cohorts of patients treated with anti-PD1 and anti-PDL1, most patients with pneumonitis have been classified as long-term responders (61%). However, the significance of this finding is not clear.</p>
							<br/><br/><br/><br/>



							<div class="marcoOSCURO wow fadeIn">

							<form>
							<br/> <br/> <br/>
							<h2>What should we do at this point?</h2>
							<br/> <br/> <br/> <br/>
							<label class="container">No idea, I would make a referral to Pulmonology.
  							<input type="radio" name="pregunta1" id="p2">
  							<span class="checkmark"></span>
							</label>
							<br/>
							<label class="container">The most likely reason is pneumonia. Antibiotic therapy and radiological control in 1 week.
								<input type="radio" name="pregunta1" id="p3">
								<span class="checkmark"></span>
							</label>
							<br/>
							<label class="container">Surely it is a pneumonitis due to Nivolumab, but it is not serious. Regimen of corticosteroids and radiological control.
								<input type="radio" name="pregunta1" id="p4">
								<span class="checkmark"></span>
							</label>
							<br/>
							<label class="container">In the event of different diagnoses, stop Nivolumab, begin corticosteroid therapy and antibiotic therapy. Request flexible bronchoscopy for more data.
								<input type="radio" name="pregunta1" id="p1">
								<span class="checkmark"></span>
							</label>
							</form>


							<div class="pregunta wow fadeIn" data-wow-duration="1s">
								<a href="#"><img onclick="resultado();return false;" src="images/profesora.png" alt="" height="90px"/></a>
							</div>







								<div id="flotante" style="display:none;">
									<br/><br/>
									<h2>Correct!</h2>
									<br/>
									<h2>The correct therapeutic decision would be<span class="negrita">:</span></h2>
									<br/> <br/>
									<p><span class="negrita">•</span> Stop Nivolumab</p>
									<br/>
									<p><span class="negrita">•</span> Start prednisone 80 mg/day orally and amoxicillin-clavulanic 875/125 every 8 hours, 1 week</p>
									<br/>
									<p><span class="negrita">•</span> Request blood cultures, pneumonia antigens in blood and urine and fibre-optic bronchoscopy (FBS) for sampling</p>
									<br/>
									<p><span class="negrita">•</span> Make an appointment with the patient in 48 hours for radiological control</p>
									<br/>
									<p>At 48 hours, the patient reported an improvement in cough and dyspnoea, the chest X-ray has improved, and bronchoaspiration obtained in the FBS confirmed a clear lymphocyte predominance that was confirmed with all the negative cultures. Cytology did not confirm malignant cells.</p>
									<br/>
									<p>With these new data, we oriented the clinical picture towards GRADE 2 pulmonary pneumonitis with good evolution, and decided to restart the Nivolumab and carry out a descending regimen of prednisone for 1 month until its withdrawal</p>

									<br/>


								</div>

								<div id="flotanteIncorrecto" style="display:none;">
									<br/><br/>
									<h2>This is not correct. Try again :)</h2>
								</div>
							</div>

						</div>
					</div>
				</div>
			</div>
		</div>
	</section>


	<section class="texto">
		<div class="container">
			<div class="row">
				<div class="parrafo wow zoomIn" data-wow-duration="0.5s">

					<p>Pulmonary toxicity to immunotherapy is resolved or improved in most cases by stopping the medication and adding corticosteroid therapy <span class="cursiva">(Naidoo, JCO 2017)</span>.</p>
					<br/>
					<p>The grade with which it is diagnosed and the response following the treatment are the indicators for deciding how steroids should be reduced.</p>



				</div>
			</div>
		</div>
	</section>

	<section class="counterUp">
		<div class="counter_overlay">
			<div class="container">
				<div class="row">
					<div class="main_counter_content text-center">
						<div class="col-md-12 col-sm-12 col-xs-12">


							<div class="marcoOSCURO wow fadeIn">

							<form>
							<br/><br/><br/>
							<p>In view of the good progress and the therapeutic benefit obtained from Nivolumab, it was decided to reintroduce it.</p>
							<br/><br/>
							<h2>Do you agree with the decision?</h2>

							</form>


							<div class="pregunta wow fadeIn" data-wow-duration="1s">
								<a href="#"><img onclick="mostrarB();return false;" src="images/interrogacion.png" alt="" height="40px"/></a>
							</div>







								<div id="flotanteB" style="display:none;">
									<br/><br/>

									<p>Reintroducing immunotherapy can be considered in patients who have experienced GRADE 1-2 pulmonary toxicity, always assessing the risk-benefit ratio and with strict monitoring, since it reappears in approximately 25% of patients <span class="cursiva">(Nishino, Clin Cancer Res 2016; 22(24):6051-60)</span>.</p>
									<br/>



					 </div>
					</div>
				 </div>
				</div>
			 </div>
			</div>
		 </div>
		</section>

		<section class="texto">
			<div class="container">
				<div class="row">
					<div class="parrafo wow zoomIn" data-wow-duration="0.5s">

										<img src="images/pulmon2.png" alt="" height="300px"/>

										<div class="col-md-6 col-sm-6 col-xs-12">
												<p><span class="negrita">•</span> Chest CT scan 1 month after reintroducing Nivolumab</p>
												<br/>
												<p><span class="negrita">•</span> Practical resolution of infiltrates</p>
												<br/>
												<p><span class="negrita">•</span> The local partial response persists</p>
										</div>

						</div>
					</div>
				</div>
			</section>


			<div class="separator"></div>



	<section class="tabla">
		<div class="container">
			<div class="row">
				<div class="parrafo wow zoomIn" data-wow-duration="0.5s">

					<h2>How do we define pulmonary toxicity?</h2>
					<br/>
					<p>The grades of pulmonary toxicity are defined according to the <span class="cursiva">Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 (CTCAE v4)</span></p>
					<br/> <br/>
				</div>

					<table class="vikhi-tabla wow zoomIn">
					<tr>
						<td><p>GRADE 1</p></td>
						<td><p>Absence of symptoms</p><p>Only radiological changes</p></td>

					</tr>
					<tr>
						<td width="15%"><p>GRADE 2</p></td>
						<td><p>Mild to moderate symptoms that limit exercise activities</p></td>

					</tr>
					<tr>
						<td width="15%"><p>GRADE 3</p></td>
						<td><p>Severe symptoms causing patient dependence in daily living activities Hypoxia/respiratory failure</p></td>

					</tr>
					<tr>
						<td width="15%"><p>GRADE 4</p></td>
						<td><p>Respiratory failure requiring orotracheal intubation</p></td>
					</tr>
					</table>
				</div>
			</div>
		</div>
	</section>



	<section class="tabla">
		<div class="container">
			<div class="row">
				<div class="parrafo wow zoomIn" data-wow-duration="0.5s">

					<h2>Management of pulmonary toxicity</h2>
					<br/>
					<p>The management of pulmonary toxicity due to immunotherapy will depend on its level of severity. We summarise it in the following algorhythm <span class="cursiva">(Naidoo, JCO, 2016; Champiat Ann Oncol 2016, Kumar Frontiers in Pharmacology 2017):</span></p>
					<br/> <br/>
				</div>
					<table class="vikhi-tabla wow zoomIn">
					<tr>
						<th><p>GRADE</p></th>
						<th><p>Management</p></th>
						<th><p>Follow-up</p></th>
					</tr>
					<tr>
						<th width="5%"><p>1</p></th>
						<td><p><span class="negrita">•</span> Do not administer immunotherapy for 2-4 weeks</p><p><span class="negrita">•</span> Monitor symptoms every 3 days</p></td>
						<td><p><span class="negrita">•</span> If it worsens, treat according to the corresponding grade</p><p><span class="negrita">•</span> Very strict radiological control (each cycle)</p></td>
					</tr>
					<tr>
						<th width="5%"><p>2</p></th>
						<td><p><span class="negrita">•</span> Do not administer immunotherapy</p><p><span class="negrita">•</span> Oral prednisone 1 mg/kg/day or equivalent</p><p><span class="negrita">•</span> Monitoring daily/twice a week of symptoms and chest X-ray every 1-3 days</p><p><span class="negrita">•</span> Perform sputum culture to rule out microbiological cause and consider fibre-optic bronchoscopy and Pulmonology consultation</p></td>
						<td><p><span class="negrita">•</span> If the symptoms resolve within 72 hours, immunotherapy may be resumed. If not resolved, discontinue it completely</p><p><span class="negrita">•</span> In GRADE 2 recurrent pneumonitis, discontinue immunotherapy permanently</p><p><span class="negrita">•</span> Descending corticosteroid regimen for at least one month</p></td>
					</tr>
					<tr>
						<th width="5%"><p>3-4</p></th>
						<td><p><span class="negrita">•</span> Discontinue immunotherapy permanently</p><p><span class="negrita">•</span> IV Methylprednisolone 2-4 mg/kg/day or equivalent</p><p><span class="negrita">•</span> Consider prophylactic antibiotics</p><p><span class="negrita">•</span> Rule out other causes, especially infectious diseases. Perform fibre-optic bronchoscopy and consult with Pulmonology</p></td>
						<td><p><span class="negrita">•</span> After the disappearance of the symptoms, perform descending corticosteroid regimen for at least 1 month</p><p><span class="negrita">•</span> If there is no response within 48 hours, consider adding an immunosuppressant (Cyclophosphamide or infliximab)</p></td>
					</tr>
					</table>
				</div>
			</div>
		</div>
	</section>


	<section>
	 <div class="container">
		 <div class="row">

			 <div class="wedo_content_area">

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contornoActivo wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad01.html"><h4 class="gris">3.1 GASTROINTESTINAL TOX.</h4></a>
						 </div>
					 </div>
				 </div>

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contornoActivo wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad02.html"><h4 class="gris">3.2 PULMONARY TOXICITY</h4></a>
						 </div>
					 </div>
				 </div>

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contorno wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad03.html"><h4>3<span class="turquesa">.3</span> RENAL TOXICITY</h4></a>
						 </div>
					 </div>
				 </div>

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contorno wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad04.html"><h4>3<span class="turquesa">.4</span> LIVER TOXICITY</h4></a>
						 </div>
					 </div>
				 </div>

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contorno wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad05.html"><h4>3<span class="turquesa">.5</span> ENDOCRINE TOXICITY</h4></a>
						 </div>
					 </div>
				 </div>

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contorno wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad06.html"><h4>3<span class="turquesa">.6</span> CUTANEOUS TOXICITY</h4></a>
						 </div>
					 </div>
				 </div>

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contorno wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad07.html"><h4>3<span class="turquesa">.7</span> NEUROLOGICAL TOXICITY</h4></a>
						 </div>
					 </div>
				 </div>

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contorno wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad08.html"><h4>3<span class="turquesa">.8</span> OTHER TOXICITIES</h4></a>
						 </div>
					 </div>
				 </div>
			 </div>
		 </div>
	 </div>
	</section>


	<footer id="footer" class="footer">
		<div class="container">
			<div class="row">
				<div class="main_footer text-center wow zoomIn" data-wow-duration="1s">
					<p class="centrado"><a href="https://www.e-oncologia.org/"><img src="images/LOGOeonco.png" alt="" height="22px"/></a></p>
				</div>
			</div>
		</div>
	</footer>

	<!-- STRAT SCROLL TO TOP -->

	<div class="scrollup">
		<a href="#"><img src="images/up.png" alt=""/></a>
	</div>






	<script type="text/javascript" src="js/jquery/jquery.js"></script>

	<script type="text/javascript" src="js/script.js"></script>

	<script type="text/javascript" src="js/bootstrap/bootstrap.min.js"></script>

	<script type="text/javascript" src="js/fancybox/jquery.fancybox.pack.js"></script>

	<script type="text/javascript" src="js/nivo-lightbox/nivo-lightbox.min.js"></script>

	<script type="text/javascript" src="js/owl-carousel/owl.carousel.min.js"></script>

	<script type="text/javascript" src="js/test.js"></script>




	<script type="text/javascript" src="js/jquery-easing/jquery.easing.1.3.js"></script>
	<script type="text/javascript" src="js/wow/wow.min.js"></script>
	<!--<script type="text/javascript" src="js/counterup/counterup.min.js"></script>-->

	<!--<script src="http://cdnjs.cloudflare.com/ajax/libs/waypoints/2.0.3/waypoints.min.js"></script>-->
	<!--<script type="text/javascript" src="js/counterup/jquery.counterup.min.js"></script>-->


	<script type="text/javascript" src="js/isotop/isotope.min.js"></script>
	<script type="text/javascript" src="js/isotop/isotop.function.js"></script>

	<script type="text/javascript" src="js/masonry/masonry.min.js"></script>

	<script type="text/javascript" src="js/mixitup/jquery.mixitup.min.js"></script>
	<script type="text/javascript" src="js/masonry/masonry.pkgd.min.js"></script>
</body>
</html>
